getting patients
started

Help get your patient’s HyQvia journey started

There are different options for getting your patients started on treatment once a prescribing decision has been made.

Acquire HyQvia directly for infusion in your clinic

Find a specialty pharmacy provider in network that supplies HyQvia

Utilize Takeda Patient Support to coordinate treatment access

The details below can help ensure your patients are equipped with everything they need for an optimal administration experience.

HyQvia comes in a dual-vial unit—one vial of Immune Globulin Infusion 10% (Human) Solution [IG 10%] and one vial of Recombinant Human Hyaluronidase¹

Vial shown is the 20 g vial and is not actual size.

The HyQvia dose is based on the IG component, which provides the therapeutic effect. Increased dispersion and absorption of IG into the bloodstream is facilitated by the Recombinant Human Hyaluronidase.

HyQvia monthly* dosing (following ramp-up) may vary depending on whether patients are switching from intravenous immune globulin (IVIG) treatment (for CIDP and PI) or conventional SCIG treatment (for PI only).

*Every 2, 3, or 4 weeks for CIDP. Every 3 or 4 weeks for PI.

Ordering & Handling

The following presentations of HyQvia are available¹:

NDC number	Volume	Grams protein	Volume	Units
	Immune Globulin Infusion 10% (Human)		Recombinant Human Hyaluronidase
0944-2510-02	25 mL	2.5	1.25 mL	200
0944-2511-02	50 mL	5.0	2.5 mL	400
0944-2512-02	100 mL	10.0	5.0 mL	800
0944-2513-02	200 mL	20.0	10.0 mL	1600
0944-2514-02	300 mL	30.0	15.0 mL	2400

NDC	Volume	Grams protein
	Immune Globulin Infusion 10% (Human)
0944-2510-02	25 mL	2.5
0944-2511-02	50 mL	5.0
0944-2512-02	100 mL	10.0
0944-2513-02	200 mL	20.0
0944-2514-02	300 mL	30.0

NDC	Volume	Units
	Recombinant Human Hyaluronidase
0944-2510-02	1.25 mL	200
0944-2511-02	2.5 mL	400
0944-2512-02	5.0 mL	800
0944-2513-02	10.0 mL	1600
0944-2514-02	15.0 mL	2400

Working with your specialty pharmacy provider

When getting started on therapy, your patients will receive HyQvia from a specialty pharmacy provider (SPP). Here are some considerations when working with an SPP:

Is HyQvia covered under the pharmacy or medical benefit? This will impact how your office acquires HyQvia and is reimbursed
Check the patient’s health plan to see which SPPs are covered (see authorized list below)
Avoid substitution by having the healthcare provider specify “dispense as written” (DAW) on the HyQvia prescription
If the SPP form doesn't have HyQvia listed, clearly write it on the form
Confirm that the appropriate tubing, ancillaries, and/or accompanying medications are dispensed alongside HyQvia

Find an authorized HyQvia SPP

Patients prescribed HyQvia may receive It from an SPP. Check your patient’s insurance coverage to determine which SPP is within your patient’s network.

The following SPPs are authorized to dispense HyQvia:

AcariaHealth

Accredo^® Specialty Pharmacy

Advanced Infusion Care

AllianceRx Walgreens Pharmacy

BioMatrix

ContinuumRx

CVS Specialty^®

Optum Infusion Pharmacy

CenterWell Specialty Pharmacy

InfuCare Rx

KabaFusion

Kroger^® Specialty Infusion

NuFACTOR^®

Option Care Health^®

OSO Home Care

PromptCare

Soleo Health^®

Superior Biologics

Inquire with specific SPPs for current status.

All product brands or trademarks are the property of their respective owners.

Download the SPP list

Review safety information

Review Important Safety Information, including Contraindications and other specific Warnings and Precautions to consider when prescribing and monitoring patients treated with HyQvia.

See safety information

Get answers to your questions. Talk to a representative about HyQvia.

Contact a Rep

Review Dosing and Administration

Explore Access & Support

IMPORTANT SAFETY INFORMATION including BOXED WARNING for Thrombosis

INDICATIONS

HYQVIA is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients two years of age and older and for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults. HYQVIA is for subcutaneous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.

Thrombosis: Has been reported to occur following treatment with IG products, including HYQVIA and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Immunogenicity of Recombinant Human Hyaluronidase (rHuPH20): Non-neutralizing antibodies to the Recombinant Human Hyaluronidase component can develop. The clinical significance of these antibodies or whether they interfere with fertilization in humans is unknown.

Aseptic Meningitis Syndrome: Has been reported with use of IG, including HYQVIA and may occur more frequently in females. The syndrome usually begins within several hours to two days following IG treatment.

Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae.

Hemolysis: HYQVIA contains blood group antibodies which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with intravenous (IV) use of IG products, especially those containing sucrose. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation.

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema may occur with IV administered IG. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Transmittable Infectious Agents: Because HYQVIA is made from human plasma, it may carry a risk of transmitting infectious agents (e.g. viruses, other pathogens). No cases of transmission of viral diseases or variant Creutzfeldt-Jakob disease (vCJD) have been associated with HYQVIA.

Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

Adverse Reactions

The most common adverse reactions observed in >5% of patients in the clinical trials were:

Primary Immunodeficiency (PI): local adverse reactions including pain, erythema, edema, and pruritus, and systemic adverse reactions including, headache, antibody formation against Recombinant Human Hyaluronidase (rHuPH20), fatigue, nausea, pyrexia, and vomiting.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): local reactions, headache, pyrexia, nausea, fatigue, erythema, pruritus, increased lipase, abdominal pain, back pain, and pain in extremity.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use in Specific Populations

Pregnancy: Limited human data are available on the use of HYQVIA during pregnancy. The effects of antibodies to the Recombinant Human Hyaluronidase on the human embryo or fetal development are unknown. It is not known whether HYQVIA can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. HYQVIA should be given to a pregnant woman only if clearly needed.

Please click for Full Prescribing Information.

INDICATIONS

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Adverse Reactions

The most common adverse reactions observed in >5% of patients in the clinical trials were:

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): local reactions, headache, pyrexia, nausea, fatigue, erythema, pruritus, increased lipase, abdominal pain, back pain, and pain in extremity.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use in Specific Populations

Please click for Full Prescribing Information.

Reference:

HyQvia. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2024.

©2024 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA^®, the TAKEDA Logo^®, and the TAKEDA Patient Support Logo^® are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. HYQVIA^® and MYIGSOURCE™ are trademarks or registered trademarks of Baxalta Incorporated.
US-HYQ-1274v1.0 06/24

About Takeda
Privacy Notice
Terms & Conditions
Site Map
To Patient Site
Contact Us
Manage Communications Preferences
Sign Up for Updates

©2024 Takeda Pharmaceuticals U.S.A., Inc., 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA^®, the TAKEDA Logo^®, and the TAKEDA Patient Support Logo^® are registered trademarks of Takeda Pharmaceutical Company Limited. HYQVIA^® is a registered trademark of Baxalta Incorporated.
US-HYQ-1274v1.0 06/24

Thank you for visiting

You are now leaving this site and being redirected to a non-Takeda owned/managed website.

Continue

Never mind, I want to stay

Hy, healthcare professionals

The information on this website is technical in nature and has been specifically created for healthcare professionals. If you are not a healthcare professional and would like to visit the patient site, please visit www.HyQvia.com

Continue

Take me to the patient site

Thank you for visiting

You are being directed to another website.

Continue

Never mind, I want to stay

Say Hy to starting patients on HyQvia

Help get your patient’s HyQvia journey started

HyQvia comes in a dual-vial unit—one vial of Immune Globulin Infusion 10% (Human) Solution [IG 10%] and one vial of Recombinant Human Hyaluronidase1

Ordering & Handling

Working with your specialty pharmacy provider

Review safety information

Review safety information

Thank you for visiting

Hy, healthcare professionals

Thank you for visiting

Thank you for visiting

Hy, healthcare professionals

Thank you for visiting

HyQvia comes in a dual-vial unit—one vial of Immune Globulin Infusion 10% (Human) Solution [IG 10%] and one vial of Recombinant Human Hyaluronidase¹